Dr. Frederick Sancilio reports

LOBE SCIENCES ADVANCES GOVERNANCE AND CAPITAL MARKETS EXPERTISE WITH APPOINTMENT OF MR. NICK KARAKOCHUK TO THE BOARD OF DIRECTORS

Lobe Sciences Ltd. has appointed Nick Karakochuk to its board of directors as the company continues to build on the momentum established during fiscal 2025.

Mr. Karakochuk is a corporate and securities lawyer at DuMoulin Black LLP, where his practice focuses on mergers and acquisitions, public and private financing, corporate reorganizations, and governance matters. He regularly advises public and private issuers on stock exchange requirements, securities regulatory compliance and continuous disclosure obligations, and has extensive experience supporting companies through complex transactions and strategic growth initiatives.

"Nick and I have worked together since I began serving as CEO of Lobe, and I am very confident that this is the right time to bring someone with his experience onto the board," said Dr. Frederick D. Sancilio, PhD, chairman and chief executive officer of Lobe Sciences. "As we enter 2026, our focus is on disciplined execution and fostering continued momentum. Nick's expertise in governance, capital markets and complex transactions will be highly valuable as we build on the progress made in fiscal 2025, and I look forward to working with him in this expanded role."

In connection with his appointment, Mr. Karakochuk was granted an aggregate of 3.5 million restricted share units of the company in accordance with the company's equity incentive plan and applicable regulatory requirements.

About Lobe Sciences Ltd.

Lobe Sciences is a biopharmaceutical company advancing programs in rare and orphan diseases with unmet medical needs. The company is pursuing development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals Inc. and wholly owned subsidiary Altemia Inc. Lobe utilizes a global network of contract pharmaceutical service providers to conduct research and development activities under Lobe's direct supervision.

We seek Safe Harbor.